Authors
Bruno M Tomazini, Israel S Maia, Alexandre B Cavalcanti, Otavio Berwanger, Regis G Rosa, Viviane C Veiga, Alvaro Avezum, Renato D Lopes, Flavia R Bueno, Maria Vitoria AO Silva, Franca P Baldassare, Eduardo LV Costa, Ricardo AB Moura, Michele O Honorato, Andre N Costa, Lucas P Damiani, Thiago Lisboa, Letícia Kawano-Dourado, Fernando G Zampieri, Guilherme B Olivato, Cassia Righy, Cristina P Amendola, Roberta ML Roepke, Daniela HM Freitas, Daniel N Forte, Flávio GR Freitas, Caio CF Fernandes, Livia MG Melro, Gedealvares FS Junior, Douglas Costa Morais, Stevin Zung, Flávia R Machado, Luciano CP Azevedo, COALITION COVID-19 Brazil III Investigators
Publication date
2020/10/6
Journal
Jama
Volume
324
Issue
13
Pages
1307-1316
Publisher
American Medical Association
Description
Importance
Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) is associated with substantial mortality and use of health care resources. Dexamethasone use might attenuate lung injury in these patients.
Objective
To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19–associated ARDS.
Design, Setting, and Participants
Multicenter, randomized, open-label, clinical trial conducted in 41 intensive care units (ICUs) in Brazil. Patients with COVID-19 and moderate to severe ARDS, according to the Berlin definition, were enrolled from April 17 to June 23, 2020. Final follow-up was completed on July 21, 2020. The trial was stopped early following publication of a related study before reaching the planned sample size of 350 patients.
Interventions
Twenty mg of dexamethasone intravenously daily for 5 days, 10 mg of …
Scholar articles
BM Tomazini, IS Maia, AB Cavalcanti, O Berwanger… - Jama, 2020